tbuckley/cabot-search huggingface dataset:
Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, Is Active in Chemotherapy Resistant B-Cell Non-Hodgkin Lymphoma and Enhances the Anti-Tumor Activity of Chemotherapy Agents
Authors: Kai Xue, Juan Gu, Cory Mavis, Francisco Hernandez, Myron S. Czuczman, Ye Guo
Journal: Blood (2014)
Epigenetics in cancer stem cells
Authors: Tan Boon Toh, Jhin Jieh Lim, Edward Kai-Hua Chow
Journal: Molecular Cancer (2017)

Compelling evidence have demonstrated that bulk tumors can arise from a unique subset of cells commonly termed "cancer stem cells" that has been proposed to be a strong driving force of tumorigenesis and a key mechanism of therapeutic resistance. Recent advances in epigenomics have illuminated key mechanisms by which epigenetic regulation contribute to cancer progression. In this review, we present a discussion of how deregulation of various epigenetic pathways can contribute to cancer initiation and tumorigenesis, particularly with respect to maintenance and survival of cancer stem cells. This information, together with several promising clinical and preclinical trials of epigenetic modulating drugs, offer new possibilities for targeting cancer stem cells as well as improving cancer therapy overall.
A Critical Role for N- and O-Linked Carbohydrates In Modulating Von Willebrand Factor Clearance In Vivo
Authors: Emily McRae, Orla Rawley, Hendrik Nel, Rachel Therese McGrath, Gudmundur Bergsson, Alain Chan, Roger Preston, Nico van Rooijen, Padraic Fallon, James S O'Donnell
Journal: Blood (2011)
Balancing Acute Graft Versus Host Disease (aGVHD) and Survival after Peripheral Allogeneic Stem Cell Transplantation (SCT) in Hematological Malignancies: A Potential for Graft Engineering.
Authors: Ayman Saad, Mohammed Almubarak, Abraham Kanate, Aaron Cumpston, Kathy Watkins, Regina Buckhalter, Pam Bunner, Gerry Hobbs, Michael Craig
Journal: Blood (2007)
Loss of Endothelial CXCR7 Impairs Vascular Homeostasis and Cardiac Remodeling After Myocardial Infarction
Authors: Huifeng Hao, Sheng Hu, Hong Chen, Dawei Bu, Liyuan Zhu, Chuansheng Xu, Fei Chu, Xingyu Huo, Yue Tang, Xiaogang Sun, Bi-Sen Ding, De-Pei Liu, Shengshou Hu, Miao Wang
Journal: Circulation (2017)

Background: Genome-wide association studies identified the association of the CXCL12 genetic locus (which encodes the chemokine CXCL12, also known as stromal cell–derived factor 1) with coronary artery disease and myocardial infarction (MI). Unlike CXCR4, the classic receptor for CXCL12, the function of CXCR7 (the most recently identified receptor) in vascular responses to injury and in MI remains unclear. Methods: Tissue expression of CXCR7 was examined in arteries from mice and humans. Mice that harbored floxed CXCR7 and Cdh5 -promoter driven CreERT2 were treated with tamoxifen to induce endothelium-restricted deletion of CXCR7. The resulting conditional knockout mice and littermate controls were studied for arterial response to angioplasty wire injury and cardiac response to coronary artery ligation. The role of CXCR7 in endothelial cell proliferation and angiogenesis was determined in vitro with cells from mice and humans. The effects of adenoviral delivery of CXCR7 gene and pharmacological activation of CXCR7 were evaluated in mice subjected to MI. Results: Injured arteries from both humans and mice exhibited endothelial CXCR7 expression. Conditional endothelial CXCR7 deletion promoted neointimal formation without altering plasma lipid levels after endothelial injury and exacerbated heart functional impairment after MI, with increased both mortality and infarct sizes. Mechanistically, the exacerbated responses in vascular and cardiac remodeling are attributable to the key role of CXCR7 in promoting endothelial proliferation and angiogenesis. Impressively, the impaired post-MI cardiac remodeling occurred with elevated levels of CXCL12, which was previously thought to mediate cardiac protection by exclusively engaging its cognate receptor, CXCR4. In addition, both CXCR7 gene delivery via left ventricular injection and treatment with a CXCR7 agonist offered cardiac protection after MI. Conclusions: CXCR7 represents a novel regulator of vascular homeostasis that functions in the endothelial compartment with sufficient capacity to affect cardiac function and remodeling after MI. Activation of CXCR7 may have therapeutic potential for clinical restenosis after percutaneous coronary intervention and for heart remodeling after MI.
Lung cancer — major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Authors: Ramón Rami‐Porta, Hisao Asamura, William D. Travis, Valerie W. Rusch
Journal: CA A Cancer Journal for Clinicians (2017)

Answer questions and earn CME/CNE The revision for the eighth edition of the tumor, node, and metastasis (TNM) classification of lung cancer was based on analyses of the International Association for the Study of Lung Cancer database, which included 77,156 evaluable patients diagnosed with lung cancer from 1999 to 2010. Among tumor (T) descriptors, the following new tumor-size groups were created: T1a, ≤1 cm; T1b, >1 to 2 cm; T1c, >2 to 3 cm; T2a, >3 to 4 cm; T2b, >4 to 5 cm; T3, >5 to 7 cm; and T4, >7 cm. Tis and T1mi were introduced for adenocarcinoma in situ and minimally invasive adenocarcinoma, respectively. Endobronchial tumors located <2 cm from the carina have better prognosis than those with any other T3 descriptor and were classified as T2. Total atelectasis/pneumonitis was classified as a T2 descriptor, because it has a T2 prognosis. Diaphragmatic invasion is now T4. Visceral pleural invasion remains unchanged, and mediastinal pleura invasion, which is seldom used, disappears as a T descriptor. The lymph node (N) component descriptors are unchanged, but the number of involved nodal stations has prognostic impact. For the metastasis (M) component, M1a (intrathoracic metastases) remains unchanged, but extrathoracic metastases are divided into a single extrathoracic metastasis (new M1b) and multiple extrathoracic metastases in a single organ or multiple organs (M1c). Stage IA is now divided into IA1, IA2, and IA3 to accommodate T1a, T1b, and T1cN0M0 tumors, respectively; all N1 disease is stage IIB except for T3-T4N1M0 tumors, which are stage IIIA; a new stage IIIC is created for T3-T4N3M0 tumors; and stage IV is divided into IVA (M1a and M1b) and IVB (M1c). This revision enhances our capacity for prognostication and will have an important impact in the management of patients with lung cancer and in future research. CA Cancer J Clin 2017;67:138-155. © 2017 American Cancer Society.
Preliminary Results of Combined Haploidentical-Cord Blood Transplantation for Patients Lacking HLA Identical Donors
Authors: Elizabeth Shima Rich, Andrew Artz, Theodore Karrison, Amittha Wickrema, Loren Joseph, Lucy Godley, Olatoyosi Odenike, Justin Kline, Paula del Cerro, John M Cunningham, Richard A. Larson, Wendy Stock, Koen van Besien
Journal: Blood (2008)
IMPS-36RNA NANOPARTICLE VACCINES RE-PROGRAM HOST-IMMUNITY AGAINST GLIOBLASTOMA INDUCING THERAPEUTIC ANTI-TUMOR ACTIVITY
Authors: Elias Sayour, Gabe De Leon, Christina Pham, Catherine Flores, Luis Sanchez-Perez, Duane Mitchell
Journal: Neuro-Oncology (2015)

INTRODUCTION: Glioblastoma (GBM) remains invariably associated with poor patient outcomes thus necessitating development of more targeted therapeutics. To circumvent the challenges associated with cellular therapeutics, we developed a novel treatment platform, which leverages the use of commercially available and clinically translatable nanoparticles (NPs) that can be combined with tumor derived RNA to peripherally activate T cells against GBM antigens. Although cancer vaccines have suffered from weak immunogenicity, we have advanced a NP vaccine formulation that can dramatically reshape a host's regulatory immune profile through combinatorial delivery of tumor RNA encoding for GBM antigens and RNAs encoding for immunomodulatory molecules to mediate long-lived T cell persistence. OBJECTIVE: We sought to assess if vaccination with amplified tumor derived RNA encapsulated in lipophilic NPs could be assembled to target antigen presenting cells (APCs) in vivo and induce therapeutic anti-tumor immunity in pre-clinical murine GBM models. RESULTS: We identified a clinically translatable NP formulation for the delivery of RNA to APCs that induces in vivo gene expression and preserves RNA stability over time. We showed that RNA-NPs induce global changes in B7 co-stimulatory molecules and MHC class II expression on CD11c expressing APCs. RNA-NPs vaccines increase systemic levels of monocyte chemotactic protein-1 (MCP-1) and increase the percentage of CD11c+ cells at target sites. White blood cells from target organs (spleen and livers) of vaccinated mice induce de novo antigen specific immune responses in naive mice. T cell immunity elicited by RNA-NP vaccination was superior to peptide vaccines in CFA, enhanced through co-encapsulation of RNA encoding GM-CSF or viral PAMPs (pathogen associated molecular patterns) from hepatitis C, and engendered therapeutic anti-tumor efficacy against a radiation and temozolomide resistant GBM murine model. CONCLUSION: Combinatorial RNA-NPs represent a novel therapeutic platform for GBM patients that can be commercialized as an ‘off the shelf’ vaccine to re-program host-immunity.
Mature Results of BEAM/High-Dose Rituximab Vs BEAM/Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) and Autologous Stem Cell Transplantation (ASCT) for Relapsed CD20+ Follicular and Diffuse Large B-Cell Lymphoma: Survival Outcomes and Risk of Secondary Malignancies
Authors: Lisa Zipp, Rima M Saliba, Rosamar Valverde, Grace-Julia Okoroji, Martin Korbling, Barry I Samuels, Lynne V. Abruzzo, Amin M Alousi, Borje S Andersson, Chitra M Hosing, Bill Erwin, Paolo Anderlini, Uday R Popat, Partow Kebriaei, Homer A Macapinlac, Richard Champlin, Issa F. Khouri
Journal: Blood (2011)
Attempts to Optimize Post-Induction Treatment in Childhood Acute Myeloid Leukemia without Core Binding Factors: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG)
Authors: Daiichiro Hasegawa, Akio Tawa, Daisuke Tomizawa, Tomoyuki Watanabe, Akiko Saito, Kazuko Kudo, Takashi Taga, Shotaro Iwamoto, Akira Shimada, Kiminori Terui, Hiroshi Moritake, Akitoshi Kinoshita, Hiroyuki Takahashi, Hideki Nakayama, Katsuyoshi Koh, Hisato Kigasawa, Yoshiyuki Kosaka, Hayato Miyachi, Keizo Horibe, Tatsutoshi Nakahata, Souichi Adachi
Journal: Blood (2012)
Ipilimumab in patients with melanoma brain metastases, a single-center experience in an expanded access program.
Authors: Stephanie Du Four, Sofie Wilgenhof, Amelie Clementine Seghers, Johnny Duerinck, Bart Neyns
Journal: Journal of Clinical Oncology (2012)

e19027 Background: patients (pts) diagnosed with melanoma brain metastases (MBM) have a poor prognosis with conventional treatment options. Ipilimumab (IPI) is a CTLA-4 blocking monoclonal antibody with established activity in patients (pts) with pretreated advanced melanoma. Methods: observational study on the clinical outcome of melanoma pts with a prior diagnosis of MBM among pts treated with IPI (3 mg/kg q3wks x4, allowing for retreatment after a PFS of &gt;24 wks) in an expanded access program at a single center. Results: among the 50 pts who initiated IPI treatment between April 2010 and May 2011, 16 pts had been diagnosed with MBM. Only 1 pt had a solitary MBM, all other pts had &gt; 3 MBM. Baseline characteristics for pts with- and without MBM: M/F 8/8 vs. 20/14; mAge 44- vs. 50y; BRAF V600-mut/wt 10/6 vs 19/15; stage IV-M1c/-a&amp;b 16/0 vs 31/3; WHO-PS 0-1/2 9/7 vs 30/4; LDH &gt;ULN 10/6 vs 23/11; CRP &gt;ULN 10/6 vs 20/14; ALC&lt;1000/mm³ 3/13 vs 11/23. All pts were pretreated with DTIC; 3 pts with stereotactic (stRT), 7 pts with WBRT, and 2 pts with WBRT followed by a stRT boost; 4 pts had no prior therapy for MBM. 7/16 pts with- vs. 24/34 pts without MBM completed IPI-treatment; 3/16 pts with- vs 8/34 pts without MBM had IPI-retreatment. Adverse events were managed following established guidelines and were generally mild/reversible (&lt;20% pts gr3-, none gr4/5) and similar in pts with- or without MBM at the exception of symptomatic radiation necrosis of the brain (RNB) observed in 3 pts (1x gr2, 2x gr3). Following surgery (1pt), and corticotherapy (3pts) all pts recovered their RNB related symptoms. Best objective tumor response (BOR) by RECIST outside the CNS in pts with- vs without MBM was 1PR vs. 1CR/2PR/4SD; according to the immune-related response criteria: 3PR vs. 1CR/2PR/7SD. After a median follow-up of 18 months, 32 pts have died (11/16 with- vs. 21/34 without MBM). The probability for OS was not significantly different for pts with- or without MBM (HR .76 [95%CI 0.36-1.59]; p: .475 by Log-Rank test). Conclusions: in our single-center experience with IPI for pts with advanced melanoma treated in an EAP, the probability for OS for patients with a prior history of MBM was not significantly different from pts without a prior history of MBM.
Wilm's Tumor 1 Protein Confers TRAIL Resistance in Myeloid Leukemia Cells Through Bcl-Xl
Authors: Hima Bansal, Theresea Siefert, Divya Chakravarthy, Manjeet Rao, Gail E Tomlinson, Swaminathan Padmanabhan, Sanjay Bansal
Journal: Blood (2011)
Locus coeruleus reports changes in environmental contingencies
Authors: Susan J. Sara
Journal: Behavioral and Brain Sciences (2016)

The GANE (glutamate amplifies noradrenergic effects) model proposed by Mather et al. attempts to explain how norepinephrine enhances processing in highly activated brain regions. Careful perusal of the sparse data available from recording studies in animals reveals that noradrenergic neurons are excited mainly by any change in the environment - a salient, novel, or unexpected sensory stimulus or a change in behavioral contingencies. This begets the "network reset hypothesis" supporting the notion that norepinephrine promotes rapid cognitive and behavioral adaption.
David Oliver: Are hospitals heading the same way as prisons?
Authors: David Oliver
Journal: BMJ (2017)

In 2016 England’s jails faced riots,1 damning inspection reports on conditions,2 and tales of ready access to drugs.3 The latest and largest riot was at HMP Birmingham, where officers lost control for 48 hours.4

Widespread coverage has been given to prison overcrowding,56 superannuated buildings,78 and prison officers’ numbers, workload, and morale.9 Unions, campaigning charities, and the inspectorate have flagged concerns repeatedly.10

We in NHS hospitals can empathise. Overcrowding, short staffing, and low morale put patients and organisations at risk. Acute activity, overcrowding, and delayed transfers are at unprecedented levels: we’re …
What topics do patients and caregivers consider most important for support groups? An evidence-based analysis of 3,728 participants.
Authors: R. J. Gralla, K. D. Morse, C. N. Rittenberg, J. A. Petersen, K. Burg, B. J. Davis, C. Sison, L. M. Rosen, M. Lesser
Journal: Journal of Clinical Oncology (2011)

9107 Background: Cancer support groups are conducted at nearly all cancer centers. Yet little data exist concerning what topics patients and their caregivers consider to be most important for support group discussion and presentation. We conducted a large web-based anonymous survey to determine preferences of patients and caregivers for cancer support groups to improve the ability to meet their needs. Methods: We used the established patient database of NexCura, a web-based information resource, to survey registered patients and caregivers. Demographic characteristics, clinical factors, and support group content preferences were assessed. Participants ranked 26 topics on a 5-point Likert scale weighing the importance of each item in this anonymous survey. Results: 4,402 respondents resulted in 3,728 participants (85%). Characteristics: 70% women, mean age 58 (range 20-89); the four most frequently occurring cancers in participants were breast 45%, prostate 15%, lung 6%, colorectal 5%. 90% of participants were patients and 10% caregivers; 80% of participants rated all 26 topics. The table below shows rankings by the top 2 categories (Very Important + Important) of the 10 highest rated topics (total of 26 topics). Conclusions: 1) These results represent by far the largest survey of patient and caregiver preferences for topics for support groups; such preferences should guide the content of support groups; 2)patients and caregivers ranked most topics in a fairly similar manner; 3) interestingly, decision making was rated in the top 5 most important topics; and 4) patients and caregivers rated cancer educational information more highly than social supportive issues. Topics (Top 10 rated of 26) Patients: Very Important + Important Caregivers: Very Important + Important Cancer treatment choices 95.0% 95.1% Side effects and their prevention 93.3% 95.1% Living with a cancer diagnosis 91.3% 92.3% Making decisions about care 89.9% 91.9% Talking with medical professionals 88.6% 89.5% Dealing with anxiety/depression 85.2% 92.5% Uncertainty of cancer 84.7% 86.6% Stress and stress management 84.6% 90.1% Navigating the health system 84.2% 88.2% Nutrition, appetite, and weight 83.1% 87.9%
Single Nucleotide Polymorphism Array (SNP-A) Genomic Profiling of Mantle Cell Lymphoma (MCL) Against a Large Control Database Reveals Recurring Copy Number Alterations (CNAs) and Copy Neutral Loss of Heterozygosity (CN-LOH)
Authors: Michael J. Rauh, Juraj Bodo, Eric Hsi, Bill Richendollar, Yuka Sugimoto, Jaroslaw P Maciejewski, Christine L. O'Keefe, Stephen D. Smith
Journal: Blood (2010)
A phase 2, fast real-time assessment of combination therapies in immuno-oncology trial in patients with advanced non-small cell lung cancer (FRACTION-lung)
Authors: P.M. Fracasso, D.J. Freeman, K. Simonsen, Y. Shen, M. Gupta, A. Comprelli, J.F. Gainor, M. Hellmann, L.Q. Chow, P.M. Forde, R. Govindan, T.P. Reilly, J. Cassidy
Journal: Annals of Oncology (2016)
Lingering Questions Concerning Intensive Care Unit Utilization
Authors: Joseph A. Hyder
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Levels of Circulating Endothelial Cells and Endothelial Progenitors Correlate with Disease Status and Treatment Response in Human Lymphoma Subtypes of CLL and MCL.
Authors: Jia Ruan, Maureen Ward, Lei Fan, Adam Faye, Maureen Lane, Katherine A. Hajjar, Lauren Tyrell, Peter Martin, Rebecca Elstrom, Morton Coleman, Richard R Furman, John P. Leonard
Journal: Blood (2009)
CD34+ Viability Is a Critical Determinant of the Engraftment Potential of Umbilical Cord Blood (UCB) in Double Unit Transplantation.
Authors: Andromachi Scaradavou, Katherine Smith, Rebecca Hawke, Sinda Lee, Allison Schaible, Michelle Abboud, Nancy Collins, Nancy A. Kernan, Marcel Van den Brink, Juliet N. Barker
Journal: Blood (2007)
HLA-Matched Unrelated Donor HCT after Nonmyeloablative Conditioning for Patients with Chronic Myeloid Leukemia.
Authors: Frederic Baron, M. Maris, B. Sandmaier, B. Storer, M. Stuart, P. McSweeney, J. Radich, M. Pulsipher, E. Agura, E. Petersdorf, S. Heimfeld, T. Chauncey, M.T. Little, D. Maloney, K. Blume, R. Storb
Journal: Blood (2004)
Severe Anaphylactic Reactions after Stopping Hymenoptera Venom Immunotherapy. a Clonal Mast Cell Disorder Should be Suspected
Authors: Patrizia Bonadonna, Giovanni Passalacqua, F. Reccardini, F Lodi Rizzini, Marina Mauro, M. Franchini, M. Pagani, C. Roncallo, Maria T. Costantino, Roberta Zanotti
Journal: Journal of Allergy and Clinical Immunology (2017)
The Nephroprotective Effect of Folic Acid—Only a Matter of Homocysteine?
Authors: Sebastian Cabrera, Miram Alvo, Charles Ferro
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal